Timothy Ko

Timothy Ko

Timothy Ko, Chief Executive Officer at Entheon Biomedical.Timothy Ko has a broad background in leading private ventures in the Service Sector, Investor Relations, Retail, and Technology. Timothy’s passion for the psychedelic space is shaped by firsthand knowledge of the shortcomings of the current mental health system and through his exposure to psychedelics which he credits with saving his life. Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) is a biotech R&D company developing a portfolio of Dimethyltryptamine (DMT) based psychedelic therapeutic products for treating addiction and substance use disorders.


Timothy Ko is an opinion columnist for the CEOWORLD magazine. You can follow him on LinkedIn.
Big Picture

When past and passion collide: Building a company based on personal experiences & the need for addiction recovery solutions

The Past: Dealing with addiction: Following a tumultuous home life, my brother fell into drugs at a fairly young age and spent nearly two decades struggling with addiction. Unfortunately, this is not an uncommon situation. In the United States alone, there are reportedly over 21 million people dealing with at least...